Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
When Cost Sharing Increases, More Naloxone Prescriptions Go Unfilled
07/10/2024
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due...
07/10/2024
Psych Congress Network

Advertisement

lab work
News
Dosing Starts in Pharmacokinetics Study of AD04 for Alcohol Use Disorder
07/08/2024
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of...
07/08/2024
Psych Congress Network
Video Game Treatment for Adults With ADHD Cleared by FDA
News
Video Game Treatment for Adults With ADHD Cleared by FDA
07/02/2024
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults...
07/02/2024
Psych Congress Network
Age-Dependent Association Found Between Cannabis Use and Psychosis
News
Age-Dependent Association Found Between Cannabis Use and Psychosis
06/27/2024
Cannabis use was significantly associated with psychotic disorders during adolescence, but not during young adulthood, according to results from an observational study published in Psychological Medicine. 
Cannabis use was significantly associated with psychotic disorders during adolescence, but not during young adulthood, according to results from an observational study published in Psychological Medicine. 
Cannabis use was significantly...
06/27/2024
Psych Congress Network

Advertisement

a doctor writes notes
News
Subcutaneous Olanzapine Long-Acting Injection Meets Efficacy Endpoint in Phase 3 Trial
06/25/2024
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational,...
06/25/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
ADHD Linked With Hiked Risk of Lewy Body Disease
News
ADHD Linked With Hiked Risk of Lewy Body Disease
06/25/2024
Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric...
Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric...
Attention-deficit/hyperactivity...
06/25/2024
Psych Congress Network

Advertisement

Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
A doctor takes notes on paper on a clipboard sitting on a desk
News
Third Xanomeline-Trospium Trial Shows Improvement in Schizophrenia Symptoms
06/18/2024
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was...
06/18/2024
Psych Congress Network
Young woman sleeping
News
Adolescents With Higher Adiposity More Vulnerable to Cognitive Impairments From Poor Sleep
06/13/2024
Adolescents with higher levels of adiposity may be more susceptible to the cognitive effects of sleep restriction than those with lower adiposity, according to a recent single-blind randomized crossover trial.
Adolescents with higher levels of adiposity may be more susceptible to the cognitive effects of sleep restriction than those with lower adiposity, according to a recent single-blind randomized crossover trial.
Adolescents with higher levels...
06/13/2024
Neurology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use